Specialty and Branded Pharmaceuticals Sector Outlook — September 2026

Read the report

SlidesScroll

1 of 23

←→Full screen

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › SPECIALTY AND BRANDED PHARMACEUTICALS

Specialty Pharma: Valuation Splits Across Business Models

This report shows where public pricing and precedent transactions distinguish franchise profiles across specialty pharma.

September 2026 · Prepared by NeuraCap AI · Confidential

Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E)

Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice

Sources & methodology

1

← Previous

1 / 23 · HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › SPECIALTY AND BRANDED PHARMACEUTICALS

Next →

What each page shows

The analyst’s walkthrough of the deck, page by page.

1. 01

   HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › SPECIALTY AND BRANDED PHARMACEUTICALS

   This is the cover slide identifying the sector, the report date and the primary valuation basis.

   We're opening with the Specialty and Branded Pharmaceuticals outlook as of September 2026, built on EV/Revenue (CY2027E) as the primary valuation basis. This sets the frame for everything that follows: where pricing sits across business models and what precedent deals tell us about it.

   Everything on this page

   HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › SPECIALTY AND BRANDED PHARMACEUTICALS Specialty Pharma: Valuation Splits Across Business Models This report shows where public pricing and precedent transactions distinguish franchise profiles across specialty pharma. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E) Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1

2. 02
   CONTENTS

   What This Report Covers

   This slide lists the five report sections and the appendix, starting with the bottom line.

   We've structured this deck so the bottom line comes first — a reader who stops after section one still gets the full story. From there we move through the landscape, valuation and situations, precedent transactions, and strategic implications. This ordering keeps the argument accessible even under time pressure.

   Everything on this page

   CONTENTS What This Report Covers 01 The Bottom Line Specialty Pharma Supports Several Routes to Premium Pricing 02 The Landscape Business Model and Revenue Durability Frame the Valuation Case 03 Valuation & Situations Premium Pricing Spans Business Models and Demands a Durable Forecast 04 Precedent Transactions Precedent Transactions Price Specialty Assets on a Wide Range 05 Strategic Implications Higher Pricing Sits with Durable Revenue and Balanced Execution 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2

3. 03
   01 · THE BOTTOM LINE

   Specialty and Branded Pharmaceuticals Splits Three Ways: Pipelines, Hybrid Portfolios and Diversified Platforms

   This slide summarizes the report's core finding that the sector splits into three business models with distinct pricing.

   We find that Specialty and Branded Pharmaceuticals prices in three groups — pipeline-led, hybrid portfolio and diversified platform businesses — using EV/Revenue (CY2027E) as the practical lens, since forward revenue coverage is broader than forward EBITDA coverage. The sector median sits at 2.7x, but the premium end reaches 5.1x against 1.0x at the discount end, and that gap persists even though both are priced on the same forward revenue base. Revenue quality — gross-to-net durability, formulary access and remaining exclusivity — is what gives the multiple its commercial meaning. So the practical takeaway is that balanced execution, not growth alone, is what the market appears to reward most.

   Everything on this page

   01 · THE BOTTOM LINE Specialty and Branded Pharmaceuticals Splits Three Ways: Pipelines, Hybrid Portfolios and Diversified Platforms The full story on one page · figures on EV / Revenue (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (21 of 25 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (22 of 25 companies), so this report follows it. Qualitative characterisations are NeuraCap views. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 Forward Revenue Is the Practical Valuation Lens 21 of 25 names have a forward revenue estimate, and the middle of the range is 2.7x. Revenue offers the broader comparison because only 13 of 25 names have meaningful forward EBITDA, often reflecting launch investment. 2 The Two Ends Carry Very Different Expectations The premium end sits at 5.1x, compared with 1.0x at the discount end. Because both use CY2027E revenue, the gap remains after forecast growth has already entered the denominator. 3 Revenue Quality Gives the Multiple Its Commercial Meaning Gross-to-net durability, formulary access and remaining exclusivity shape how owners can defend forecast revenue. Portfolio breadth and delivery complexity can also strengthen the case around durability. 4 Balanced Execution Sits Above Growth Alone On the 13 names with both growth and margin estimates, the 3 names clearing both bars sit at 4.8x. The 4 growth-only names sit at 1.6x, showing that forecast growth can carry very different pricing. 2.7x Sector median EV/Revenue CY2027E consensus · EV/Revenue is the lens because practitioners price this growth set on revenue and 2 of 25 names are… 5.1x Premium end EV/Revenue vs 1.0x at the discount end top quartile (n=6) against bottom quartile (n=4) on EV/Revenue — the spread the report explains 41 Transactions with disclosed terms 125 recorded in this tier · 3 told as case studies, the full list in the appendix

4. 04
   SECTION 02

   02

   This divider introduces the section on business model and revenue durability.

   We turn now to the business models themselves — pipelines, hybrid portfolios and diversified platforms each expose owners to different launch, payer and exclusivity questions. Understanding these differences is what makes the valuation gap in the next section interpretable.

   Everything on this page

   SECTION 02 02 THE LANDSCAPE Business Model and Revenue Durability Frame the Valuation Case Pipelines, hybrid portfolios and diversified platforms expose owners to different launch, payer and exclusivity questions. 02 of 06 Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4

5. 05
   02 · MARKET MAP

   Capital Sits Across Three Specialty Pharma Models: Pipelines, Hybrid Portfolios and Diversified Platforms

   This slide maps the covered companies into three business-model groups with each group's median valuation.

   We group the covered universe into three specialty pharma models and show where capital sits across each on a median EV/Revenue (CY2027E) basis. This grouping is what lets us explain why some franchises carry a premium and others don't. It's the foundation for the valuation analysis that follows.

   Everything on this page

   02 · MARKET MAP Capital Sits Across Three Specialty Pharma Models: Pipelines, Hybrid Portfolios and Diversified Platforms 25 approved companies grouped by business segment · median EV / Revenue (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 PRE-COMMERCIAL BRANDED THERAPEUTIC PIPELINES 12 cos median 2.7x ASND AUPH TRVI ARDX PHAT TBPH ZVRA ACHV HRTX SLGL AKBA UNCY Pipeline-led businesses concentrate value in approval, launch execution and the protected life of a focused asset base. SPECIALTY BRAND AND AUTHORIZED-GENERIC HYBRID PORTFOLIOS 9 cos median 2.3x TAK ZTS ALKS INDV RGC ANIP PCRX EOLS DERM Hybrid portfolios combine branded economics with established commercial infrastructure and shared field-force potential. DIVERSIFIED BRANDED PHARMACEUTICAL PLATFORMS 3 cos median 2.7x NVS GSK SCLX Diversified platforms spread product and patent-cliff exposure across broader portfolios. ADJACENT: DIAGNOSTICS-ATTACHED SPECIALTY PHARMA PLATFORMS 1 cos 2.2x · 1 rated OPK The diagnostics-attached model links specialty products with a distinct channel and reimbursement profile.

6. 06
   02 · LANDSCAPE

   Franchise Models Differ, and so Do the Routes to Durable Revenue

   This slide explains what each business-model segment does and why its revenue durability differs.

   We lay out what each segment does commercially and why its route to durable revenue looks different — pipeline businesses depend on launch execution, hybrid portfolios blend legacy and new brands, and diversified platforms spread risk across a broader base. Full company-level detail sits in the appendix for anyone who wants to trace a specific name. These structural differences are what ultimately show up in the valuation gap we quantify next.

   Everything on this page

   02 · LANDSCAPE Franchise Models Differ, and so Do the Routes to Durable Revenue Segment view of the approved universe · EV / Revenue (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/Revenue Names to know What they do — and why it matters Pre-commercial branded therapeutic pipelines 12 48% 2.7x Ascendis Pharma A/S (ASND) · Aurinia Pharmaceuticals Inc. (AUPH) · +10 more Milestones concentrate the value. Approval, payer access and launch uptake can change the revenue base quickly, while sole-asset concentration keeps the exclusivity clock central. Specialty brand and authorized-generic hybrid portfolios 9 36% 2.3x Takeda Pharmaceutical Company Limited (TAK) · Zoetis Inc. (ZTS) · +7 more Commercial infrastructure carries weight. Shared prescriber coverage, disciplined gross-to-net management and portfolio mix determine how efficiently these businesses support multiple products. Diversified branded pharmaceutical platforms 3 12% 2.7x Novartis AG (NVS) · GSK plc (GSK) · +1 more Breadth spreads portfolio risk. Broader product sets can absorb individual patent cliffs more effectively, making capital allocation and pipeline replenishment central to the value case. Adjacent: diagnostics-attached specialty pharma platforms 1 4% 2.2x n=1 OPKO Health, Inc. (OPK) Channel economics shape performance. Diagnostics attachment adds a distinct reimbursement and customer pathway, so channel fit matters alongside pharmaceutical demand.

7. 07
   SECTION 03

   03

   This divider introduces the section on public market valuation and premium pricing.

   We move next into how the market actually prices this sector today. The forward revenue lens already credits expected growth, which raises the bar for any business trying to defend a premium multiple.

   Everything on this page

   SECTION 03 03 VALUATION & SITUATIONS Premium Pricing Spans Business Models and Demands a Durable Forecast The forward revenue lens already credits expected growth, raising the bar for defending a premium. 03 of 06 Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7

8. 08
   03 · PUBLIC MARKET VALUATION

   Premium Pricing Persists After Forecast Growth Enters the Revenue Base

   This slide ranks all rated companies by EV/Revenue (CY2027E) around a sector median of 2.7x.

   We rank the full rated set on EV/Revenue (CY2027E), with a sector median of 2.7x, using this basis because it's the industry standard here and because a portion of the covered names are loss-making on forward EBITDA. The spread across the set shows premium pricing persisting well after forecast growth has already entered the revenue base. So a name trading above median is being asked to defend growth the market has already priced in.

   Everything on this page

   03 · PUBLIC MARKET VALUATION Premium Pricing Persists After Forecast Growth Enters the Revenue Base EV / Revenue (CY2027E) · all 21 rated companies, sorted descending · sector median 2.7x · EV/Revenue is the lens because practitioners price this growth set on revenue and 2 of 25 names are loss-making on forward EBITDA · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (21 of 25 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (22 of 25 companies), so this report follows it. Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / Revenue (CY2027E) basis. Panel commentary is a NeuraCap view. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 5.1x CORE · median 2.2x DISCOUNT · median 1.0x Sector median 2.7x WHAT SEPARATES THE TWO ENDS Premium pricing spans models. The premium end carries a 5.1x CY2027E EV / Revenue multiple, with pipeline-led, hybrid and diversified names represented. Discount pricing marks uncertainty. The discount end sits at 1.0x, pointing to a lower market view of forecast revenue quality, durability or execution. Forward pricing tests durability. A CY2027E multiple already credits forecast growth. A premium that remains on that basis signals that investors are also underwriting durability beyond the near-term ramp.

9. 09
   03 · VALUATION DRIVERS

   Profitability Separates the Two Ends: Names Above the 29% Margin Line Carry 4.0x Against 1.6x Below It

   This slide splits the rated set by growth and margin cohorts to show which driver aligns more closely with valuation.

   We split the rated set at its own covered medians for growth and for margin, and the split is sharpest on profitability: names above the 29% margin line carry 4.0x against 1.6x below it. This is an association in the data we're showing, not a claim that margin alone causes the premium. It tells us where to focus the diligence conversation — on what supports that margin, not just on the growth number.

   Everything on this page

   03 · VALUATION DRIVERS Profitability Separates the Two Ends: Names Above the 29% Margin Line Carry 4.0x Against 1.6x Below It Median EV / Revenue (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=10; slower n=10; higher-margin n=7; lower-margin n=6). Driver readings are NeuraCap views on the supplied data — association, not causation. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/Revenue, median per cohort · growth split at 6% · EBITDA-margin split at 29% The Growth Split Runs Against a Simple Premium Story Names above the 6% growth split sit at 2.1x, while names below it sit at 2.8x. The observed pricing therefore does not support growth alone as a sufficient explanation. Profitability Changes the Reading of Growth The balanced group sits above the growth-only group, associating higher pricing with a combination of revenue growth and margin delivery. Revenue Durability Remains Central Exclusivity runway, net realised price, formulary position and refill persistence frame whether forecast revenue can hold after launch investment normalizes.

10. 10
    03 · SITUATION MAP

    Premium Pricing Includes Both Growth Leaders and Slower-Growth Franchises

    This slide places each rated company into a quadrant cut on valuation versus the sector median and growth versus the covered median.

    We map each rated name against the sector median of 2.7x and the covered growth median, and the resulting quadrants show that premium pricing includes both growth leaders and slower-growth franchises. These are observations about where each name sits, not a recommendation on any security. It's a useful starting point for asking why a specific name sits where it does.

    Everything on this page

    03 · SITUATION MAP Premium Pricing Includes Both Growth Leaders and Slower-Growth Franchises Cut on EV / Revenue vs the sector median (2.7x) (rows) and revenue growth vs the covered median (6%) (columns) · 1 rated names without the second measure are not mapped · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Premium with Growth Above-median multiple · above-median revenue growth 5 names Ascendis Pharma A/S (ASND) · Alkermes plc (ALKS) · Indivior Pharmaceuticals Inc (INDV) · +2 more These names combine above-line growth with above-line pricing. The value case rests on sustaining growth while protecting net realised price and margin quality. Premium with Slower Growth Above-median multiple · below-median revenue growth 6 names Novartis AG (NVS) · GSK plc (GSK) · Takeda Pharmaceutical Company Limited (TAK) · +3 more These names carry above-line pricing despite slower growth. Portfolio breadth, profitability or perceived revenue durability may be associated with that position. Growth Awaiting Recognition Below-median multiple · above-median revenue growth 5 names ANI Pharmaceuticals, Inc. (ANIP) · Ardelyx, Inc. (ARDX) · Evolus, Inc. (EOLS) · +2 more These names post above-line growth while remaining below the pricing line. The operating question is whether retention, payer access and cost structure can turn growth into a more durable value case. Execution and Pricing Gap Below-median multiple · below-median revenue growth 4 names OPKO Health, Inc. (OPK) · Pacira BioSciences, Inc. (PCRX) · Heron Therapeutics, Inc. (HRTX) · +1 more These names sit below both lines. Improving revenue mix, cost structure or portfolio focus would change the evidence available to investors and strategic buyers.

11. 11
    03 · GROWTH VS PROFITABILITY

    Balanced Growth and Margin Sit at the Top of the Range in the Operating Screen

    This slide plots covered companies on growth versus margin and shows the median valuation in each quadrant.

    We plot revenue growth against EBITDA margin for the companies with both estimates, cutting at the covered medians of 12% growth and 29% margin. The names that clear both bars sit at the top of the range on EV/Revenue, while growth-only names trade at a noticeably lower multiple. So balanced execution — not growth in isolation — is what the operating screen associates with the strongest pricing.

    Everything on this page

    03 · GROWTH VS PROFITABILITY Balanced Growth and Margin Sit at the Top of the Range in the Operating Screen Revenue growth (CY2026E, x-axis) vs EBITDA margin (CY2027E, y-axis) · 13 companies with both estimates · cuts at the covered medians (12% growth, 29% margin) · median EV/Revenue per quadrant · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Quadrant cuts are the covered set's medians. Quadrant medians on names with a meaningful EV/Revenue (balanced n=3; margin-only n=4; growth-only n=4; neither n=2). Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 0% 20% 40% 60% 80% 20% 40% 60% MARGIN ONLY median 3.7x BALANCED median 4.8x NEITHER median 2.3x GROWTH ONLY median 1.6x ZTS TAK GSK PCRX NVS INDV EOLS AUPH ARDX ALKS ANIP PHAT ASND x: revenue growth (CY2026E) · y: EBITDA margin (CY2027E) HOW TO READ THIS Among the 13 names with both estimates, 3 clear the 12% growth and 29% margin bars and sit at 4.8x. The 4 margin-only names sit at 3.7x, while the 4 growth-only names sit at 1.6x. The 2 names clearing neither bar sit at 2.3x. The pattern associates balanced execution with higher pricing in this sample. The growth-only median rests on 4 names and is lifted by ALKS at 4.0x. Rule of 40 (revenue growth + EBITDA margin ≥ 40%): 6 of 13 names clear it (ASND, NVS, AUPH, INDV, ANIP, PHAT).

12. 12
    03 · THE AGENDA

    The Higher Valuations Sit with Operating Models Built on Durable Revenue

    This slide frames the questions an owner or acquirer should resolve given where valuation concentrates.

    We frame this as the set of questions an owner or acquirer should be answering next, grounded in the cohort data from the prior pages. These are NeuraCap observations, not recommendations to buy or sell any security. The agenda gives the room a concrete starting point for its own diligence.

    Everything on this page

    03 · THE AGENDA The Higher Valuations Sit with Operating Models Built on Durable Revenue NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12 Protect Revenue Quality Focus the operating plan on net realised price, refill persistence, formulary access and gross-to-net discipline across priority brands. What changes the answer: The answer changes when script growth requires materially greater rebates or patient assistance. Broaden the Franchise Base Test label expansion, adjacent indications and portfolio additions that can use existing prescriber access and commercial infrastructure. What changes the answer: The answer changes when a new asset requires a separate field force, channel or reimbursement model. Match Costs to Maturity Align launch investment and field-force reach with patient starts, refill behavior and the pace of covered-lives access. What changes the answer: The answer changes when commercial productivity remains below the level needed to support the cost base. Choose Build Versus Buy Compare internal pipeline investment with acquiring brands or companies that add revenue, exclusivity runway or commercial fit. What changes the answer: The answer changes when external assets offer a clearer route to portfolio breadth than internal development.

13. 13
    SECTION 04

    04

    This divider introduces the section on precedent transactions.

    We now turn to how buyers have actually priced specialty assets in past deals. Asset maturity, portfolio fit and commercial durability remain central to reading what those buyers agreed to pay.

    Everything on this page

    SECTION 04 04 PRECEDENT TRANSACTIONS Precedent Transactions Price Specialty Assets on a Wide Range Asset maturity, portfolio fit and commercial durability remain central to interpreting what buyers agreed to pay. 04 of 06 Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13

14. 14
    04 · DEAL CASE STUDIES

    Precedent Transactions Span Mature Portfolios and Focused Specialty Assets

    This slide walks through three precedent transactions with disclosed terms as illustrative case studies.

    We walk through three precedent transactions with disclosed terms out of the broader universe, using multiples on LTM financials at announcement. The full precedent list, including transactions without disclosed terms, sits in the appendix and companion workbook. These deal multiples aren't directly comparable to the CY2027E public basis, so we don't claim a spread — but they do show what buyers have actually paid for comparable assets.

    Everything on this page

    04 · DEAL CASE STUDIES Precedent Transactions Span Mature Portfolios and Focused Specialty Assets 3 of 41 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 151 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 84 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14 Nov-2021 $17.9B Merck & Co., Inc. acquires Organon & Co. EV / LTM revenue 2.8x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The transaction broadens the evidence on what buyers agreed to pay for whole companies in the sector. HOW THE TARGET WAS VALUED Its valuation is most useful as part of the transaction range rather than as a stand-alone anchor. Apr-2026 $11.9B Sun Pharmaceutical Holdings USA, Inc. Sun Pharmaceutical Holdings USA, Inc. agreed to acquire Organon & Co. at portfolio scale. EV / LTM revenue 1.9x EV / LTM EBITDA 6.5x WHY THE DEAL HAPPENED The transaction suggests a strategy centered on adding a broad commercial franchise to an established pharmaceutical platform. Organon & Co.'s portfolio profile offers scale beyond a single focused asset. HOW THE TARGET WAS VALUED The announced value was $11.9B, equal to 1.9x revenue and 6.5x EBITDA. The revenue multiple sits below the middle of the public peer range. Aug-2025 $299M MannKind Corporation MannKind Corporation agreed to acquire scPharmaceuticals Inc. as a focused specialty addition. EV / LTM revenue 2.1x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The transaction suggests that MannKind Corporation saw value in adding a commercial specialty franchise to its existing platform. The fit points to potential relevance across commercial infrastructure and prescriber reach. HOW THE TARGET WAS VALUED The announced value was $299M at 2.1x revenue. That pricing sits below the middle of the public peer range.

15. 15
    SECTION 05

    05

    This divider introduces the section on strategic implications.

    We close the analytical sections here and move into what this means operationally. The agenda centers on revenue quality, exclusivity, cost structure and disciplined portfolio choices.

    Everything on this page

    SECTION 05 05 STRATEGIC IMPLICATIONS Higher Pricing Sits with Durable Revenue and Balanced Execution The operating agenda centers on revenue quality, exclusivity, cost structure and disciplined portfolio choices. 05 of 06 Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15

16. 16
    05 · STRATEGIC IMPLICATIONS

    The Value Agenda Centers on Revenue Durability and Balanced Execution

    This slide sets out the value agenda centered on revenue durability and balanced execution for the next twelve months.

    We set out the questions this data puts on the table for owners, management teams and boards over the next twelve months. The consistent thread is that revenue durability and balanced growth-and-margin execution are what the market appears to reward. These are NeuraCap views drawn from the analysis, not recommendations on any specific transaction.

    Everything on this page

    05 · STRATEGIC IMPLICATIONS The Value Agenda Centers on Revenue Durability and Balanced Execution NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16 FOR OWNERS Build Durability into the Operating Plan Prioritize revenue mix, payer access, refill persistence and exclusivity runway alongside growth. The peer set associates balanced growth and margin delivery with higher pricing. FOR MANAGEMENT TEAMS Concentrate Resources Where Economics Hold Direct field-force, hub services and patient assistance toward brands where net realised price and persistence support durable contribution. FOR BOARDS Test Portfolio Choices Against the Clock Evaluate capital allocation, label expansion and build-versus-buy choices against patent-cliff timing and the ability to reuse commercial infrastructure.

17. 17
    SECTION 06

    06

    This divider introduces the appendix covering the full comparable universe, methodology and sources.

    We close with the full comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives.

    Everything on this page

    SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17

18. 18
    06 · PUBLIC COMPARABLES (1 OF 2)

    Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier

    This slide lists rated public comparables on EV/Revenue (CY2027E), shaded by whether each sits above or below the sector median.

    We list the rated comparable set here, shaded against the sector median of 2.7x so it's immediately clear which names sit above and which sit below. Every ticker links back to its underlying source for anyone who wants to verify a figure directly. This gives a client the full evidentiary basis behind the rankings shown earlier in the deck.

    Everything on this page

    06 · PUBLIC COMPARABLES (1 OF 2) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (2.7x); amber marks below · 21 rated companies; 4 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 21 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥4.0x · median 5.1x · 6 companies Sol-Gel Technologies Ltd. SLGL Pre-commercial branded therapeutic pipelines $142M 94.3x -96% n/a n/a Ascendis Pharma A/S ASND Pre-commercial branded therapeutic pipelines $14.6B 6.4x 84% 36% 82 Novartis AG NVS Diversified branded pharmaceutical platforms $321B 5.3x 4% 41% 48 Theravance Biopharma Inc TBPH Pre-commercial branded therapeutic pipelines $523M 5.0x -21% n/a n/a Aurinia Pharmaceuticals Inc. AUPH Pre-commercial branded therapeutic pipelines $1.9B 4.8x 17% 65% 82 Alkermes plc ALKS Specialty brand and authorized-generic hybrid portfolios $7.8B 4.0x 24% 11% 17 CORE — 1.3x–4.0x · median 2.2x · 11 companies Zoetis Inc. ZTS Specialty brand and authorized-generic hybrid portfolios $37.3B 4.0x -2% 41% 43 Indivior Pharmaceuticals Inc INDV Specialty brand and authorized-generic hybrid portfolios $4.8B 3.5x 8% 49% 55 Takeda Pharmaceutical Company Limited TAK Specialty brand and authorized-generic hybrid portfolios $87.3B 3.0x -1% 28% 27 GSK plc GSK Diversified branded pharmaceutical platforms $126B 2.7x 3% 34% 38 Zevra Therapeutics, Inc. ZVRA Pre-commercial branded therapeutic pipelines $469M 2.7x 43% n/a n/a OPKO Health, Inc. OPK Adjacent: diagnostics-attached specialty pharma… $1.3B 2.2x -6% n/a n/a ANI Pharmaceuticals, Inc. ANIP Specialty brand and authorized-generic hybrid portfolios $2.0B 1.6x 25% 26% 38 Evolus, Inc. EOLS Specialty brand and authorized-generic hybrid portfolios $639M 1.6x 12% 10% 28 Pacira BioSciences, Inc. PCRX Specialty brand and authorized-generic hybrid portfolios $1.2B 1.5x 4% 26% 30

19. 19
    06 · PUBLIC COMPARABLES (2 OF 2)

    Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier

    This slide continues the rated public comparables list on EV/Revenue (CY2027E).

    We continue the same comparable set here, completing the full rated list shaded against the 2.7x sector median. The companion workbook carries the complete field set for every name, rated or not. This gives a client everything needed to trace any multiple referenced earlier.

    Everything on this page

    06 · PUBLIC COMPARABLES (2 OF 2) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (2.7x); amber marks below · 21 rated companies; 4 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 21 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 CORE — CONTINUED — 1.3x–4.0x · median 2.2x · 11 companies Journey Medical Corporation DERM Specialty brand and authorized-generic hybrid portfolios $175M 1.3x 32% n/a n/a Ardelyx, Inc. ARDX Pre-commercial branded therapeutic pipelines $812M 1.3x 20% 17% 45 DISCOUNT — <1.3x · median 1.0x · 4 companies Phathom Pharmaceuticals, Inc. PHAT Pre-commercial branded therapeutic pipelines $569M 1.2x 81% 29% 86 Heron Therapeutics, Inc. HRTX Pre-commercial branded therapeutic pipelines $153M 1.1x -4% n/a n/a Akebia Therapeutics, Inc. AKBA Pre-commercial branded therapeutic pipelines $128M 1.0x -16% n/a n/a Scilex Holding Company SCLX Diversified branded pharmaceutical platforms $116M 0.6x n/a n/a n/a

20. 20
    06 · PRECEDENT TRANSACTIONS (1 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This slide lists precedent transactions with disclosed terms, ordered from most recent.

    We list the disclosed-term precedent transactions here, newest first, with multiples on LTM financials at announcement. The remaining transactions beyond what's shown here sit in the companion workbook. Together, this gives a client the full precedent record needed to test today's pricing against what buyers have actually paid.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 41 transactions with disclosed terms in this tier (125 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 151 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 84 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 41 transactions shown; the rest are in the companion workbook. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 20 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Apr-2026 Sun Pharmaceutical Holdings USA, Inc. → Organon & Co. $11.9B 1.9x 6.5x Sun Pharmaceutical Holdings USA, Inc. and Organon & Co. show how a large commercial portfolio can enter the transaction record at substantial scale. Apr-2026 Garda Therapeutics, Inc. → Assertio Holdings, Inc. $166M 1.6x n/a Value shown as recorded in the filing; deal value unit unresolved. Mar-2026 Aurinia Pharma U.S., Inc. → Kezar Life Sciences, Inc. $26M 7.8x n/a Aurinia Pharma U.S., Inc. and Kezar Life Sciences, Inc. show that smaller transaction values can still carry high revenue pricing. Mar-2026 Merck Sharp & Dohme LLC → Terns Pharmaceuticals, Inc. $4.4B n/a n/a Value shown as recorded in the filing; deal value unit unresolved. Aug-2025 MannKind Corporation → scPharmaceuticals Inc. $299M 2.1x n/a MannKind Corporation and scPharmaceuticals Inc. illustrate how a specialty platform can add a complementary commercial franchise. Mar-2025 Jazz Pharmaceuticals plc → Chimerix, Inc. $736M n/a n/a Value shown as recorded in the filing; deal value unit unresolved. Mar-2025 Paratek Phamaceuticals Inc. → OptiNose Inc. n/a 2.1x n/a Value shown as recorded in the filing; deal value unit unresolved. Apr-2024 Ono Pharmaceutical Co., Ltd. → Deciphera Pharmaceuticals, Inc. n/a 6.9x n/a Dec-2023 Future Pak, LLC → Vanda Pharmaceuticals Inc. $112M 0.6x n/a Value shown as recorded in the filing; deal value unit unresolved.

21. 21
    06 · PRECEDENT TRANSACTIONS (2 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This slide continues the list of precedent transactions with disclosed terms.

    We continue the same precedent list here, completing the disclosed-term transactions shown newest first. As with the prior page, deal multiples are LTM at announcement and are not directly comparable to the public CY2027E basis. The complete set, including transactions without disclosed terms, remains available in the companion workbook for a client who wants the full record.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 41 transactions with disclosed terms in this tier (125 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 151 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 84 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 41 transactions shown; the rest are in the companion workbook. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 21 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Apr-2023 Assertio Holdings, Inc. → Spectrum Pharmaceuticals, Inc. $3.3B n/a n/a Value shown as recorded in the filing; deal value unit unresolved. Jan-2023 Chiesi Farmaceutici S.p.A. → Amryt Pharma plc n/a 2.1x n/a Nov-2022 Indivior PLC → Opiant Pharmaceuticals, Inc. n/a n/a 8.8x Value shown as recorded in the filing; deal value unit unresolved. Oct-2022 Amgen Inc. → ChemoCentryx, Inc. n/a 4.1x n/a Sep-2022 Pfizer Inc. → Biohaven Ltd. n/a 4.6x n/a Aug-2022 Innoviva Specialty Therapeutics, Inc. → La Jolla Pharmaceutical Company n/a 1.9x n/a Value shown as recorded in the filing; deal value unit unresolved. Mar-2022 Axsome Therapeutics → Sunosi (division of Jazz Pharmaceuticals plc) n/a 0.9x n/a Value shown as recorded in the filing; deal value unit unresolved. Feb-2022 Collegium Pharmaceutical, Inc. → BioDelivery Sciences International, Inc. n/a 2.7x 11.9x Value shown as recorded in the filing; deal value unit unresolved. Jan-2022 Amneal Pharmaceuticals, Inc. → Saol Therapeutics n/a 3.3x n/a Value shown as recorded in the filing; deal value unit unresolved.

22. 22
    06 · METHODOLOGY

    Sources, Assumptions and Data Quality

    This slide documents the report's sources, assumptions and data-quality treatment.

    We document how this report was built here — what was included, what was excluded, and where every underlying disclosure lives. Every figure in the body links to the record it came from, and where a figure has no link, the appendix names its source and basis. This is the reference page for anyone who wants to audit a specific number.

    Everything on this page

    06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice 22 VALUATION BASIS Primary valuation basis: EV / Revenue on CY2027E consensus (21 of 25 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (22 of 25 companies), so this report follows it. EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Specialty and Branded Pharmaceuticals and it clears the coverage gate with 21 of 25 companies (84%). P / E is carried as a cross-check. A revenue lens is used rather than a profit multiple because the set is not consistently profitable on a forward basis (13 of 25 names with a meaningful EBITDA). DATA QUALITY & EXCLUSIONS 58 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 828 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (827) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.

23. 23

    Premium Pricing Appears Across Several Franchise Profiles in the Peer Set.

    This closing slide restates that premium pricing appears across several franchise profiles in the peer set.

    We close on the same finding we opened with: premium pricing appears across several franchise profiles in this peer set, not just one. This wraps the sector story to the conclusion the cover set up. The companion tables carry the full universe, the exclusion ledger and the complete source index for any figure a client wants to trace.

    Everything on this page

    Premium Pricing Appears Across Several Franchise Profiles in the Peer Set. NeuraCap AI — Specialty and Branded Pharmaceuticals Coverage September 2026 · Prepared by NeuraCap AI · Confidential Specialty and Branded Pharmaceuticals Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 23

More coverage in Health Care

• Bi-Weekly Update · Sep 28, 2026Specialty and Branded Pharmaceuticals Bi-Weekly Industry Events & M&A Update — September 14–28, 2026
• Sector Report · Sep 28, 2026Medical Imaging Equipment Sector Outlook — September 2026
• Bi-Weekly Update · Sep 28, 2026Neurology and CNS Therapeutics Bi-Weekly Industry Events & M&A Update — September 14–28, 2026
• Bi-Weekly Update · Sep 28, 2026Medical Imaging Equipment Bi-Weekly Industry Events & M&A Update — September 14–28, 2026